Accustem Sciences (ACUT) Total Liabilities (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Total Liabilities of $5.4 million for Q1 2026, up 46.26% year-over-year from $3.7 million in Q1 2025, and up 9.51% quarter-over-quarter from $5.0 million in Q4 2025.
Accustem Sciences (ACUT) Total Liabilities (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Total Liabilities for 6 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 46.26% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 46.26% YoY), while the FY2025 annual figure was $5.0 million, up 47.17% from the prior year.
- Total Liabilities improved to $5.4 million in Q1 2026 per ACUT's latest filing, from $5.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $5.4 million in Q1 2026 and bottomed at $561109.0 in Q1 2022.
- Historically, Total Liabilities has averaged $2.7 million across 5 years, with a median of $2.7 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 159.78% — and 2025, when it surged 35.99%.
- Accustem Sciences' Total Liabilities stood at $1.1 million in 2022, then surged by 108.06% to $2.2 million in 2023, then soared by 49.82% to $3.4 million in 2024, then soared by 47.17% to $5.0 million in 2025, then climbed by 9.51% to $5.4 million in 2026.
- Business Quant data shows ACUT's Total Liabilities at $5.4 million in Q1 2026, $5.0 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 5.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.42 Mn |
| Dec 31, 2025 | 4.95 Mn |
| Sep 30, 2025 | 4.48 Mn |
| Jun 30, 2025 | 4.15 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.14 Mn |
| Jun 30, 2023 | 1.77 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 824,934.00 |
| Jun 30, 2022 | 731,390.00 |
| Mar 31, 2022 | 561,109.00 |
| Dec 31, 2021 | 702,700.00 |